Boehringer Ingelheim Sued For €23M Over Diabetes Drug IP

Law360, London (June 17, 2020, 6:59 PM BST) -- Biopharmaceutical licensing company Royalty Pharma has sued Boehringer Ingelheim in a U.K. court, saying the German drug giant reneged on a 2015 deal by unilaterally reducing the patent royalties it paid for its diabetes treatment.

Royalty Pharma Collection Trust's amended High Court claim seeks the court's confirmation of its interpretation of the licensing agreement between the two companies and payment of the alleged shortfall, totaling more than €23 million ($25.8 million).

The dispute is rooted in a 2005 licensing deal between Boehringer Ingelheim and another biopharmaceutical company, Prosidion Ltd., which Royalty Pharma acquired in 2011. The license is linked to DP-IV inhibitors,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!